BI-1910 is under clinical development by BioInvent International and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-1910’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-1910 overview
BI-1910 is under development for the treatment of solid tumors including hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). The drug candidate is developed based on n-CoDeR antibody library and F.I.R.S.T. technology platform. It acts by targeting alpha tumor necrosis factor receptor 2 (TNFRSF1B). It is administered through intravenous route.
BioInvent International overview
BioInvent International (BioInvent) focuses on the research and development of antibodies for the treatment of cancer. The company uses n-CoDeR, an inhouse platform for developing immuno-oncology drugs. n-CoDeR is an antibody library used for the rapid selection, screening and identification of antibodies. The company’s pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers. It has collaborations and partners with several leading pharmaceutical companies including Pfizer, MSD and Transgene for the co-development of its drug candidates. BioInvent is headquartered in Lund, Sweden.
For a complete picture of BI-1910’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
